You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease
SBC: SELEXYS PHARMACEUTICALS CORPORATION Topic: NIDDKDESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal tract that affects some 500,000 patients in the US. Selexys Pharmaceuticals is developing a fully human anti-PSGL- ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Novel DNA Polymerase Inhibitors as Gram-Positive Antibacterial Agents
SBC: CRESTONE, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The alarming increase in incidence of infections caused by drug-resistant bacteria has created an urgent need for new antibacterial agents. We have discovered and optimized a novel class of antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. These agents exhibit broad spectrum activity against Gram-positive bacteria, including ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Automation of quantitative DIC microscopy for 3D live-cell imaging using programm
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NCRRDESCRIPTION (provided by applicant): The primary objective proposed is to utilize Boulder Nonlinear System's (BNS) spatial light modulator (SLM) technology to automate the Cogswell group's recently-developed quantitative DIC microscope (Q-DIC) and make it accessible to biologists in the marketplace. Q-DIC is a full-field (non-scanning) phase imaging technique which provides optical path length mea ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting IL-11 Analog for Treating Acute Radiation Syndrome
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting in death. Interleukin-11 (IL-11) is a ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Multiplex Diagnostic for Enteric Category B Pathogens and Intestinal Biomarkers
SBC: TECHLAB, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Our goal is development of a multiplex immunodiagnostic panel specific for Giardia, Cryptosporidium, E. histolytica, and shiga toxin-producing Shigella and E. coli detection in stool. Additional effort will quantify the fecal biomarkers lactoferrin and hemoglobin, indicators of intestinal inflammation and hemorrhage. The full multiplex panel will provide rapid ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Novel anti-viral agents to treat influenza
SBC: ALEXANDER BIODISCOVERIES, LLC Topic: NIAIDDESCRIPTION (provided by applicant): Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,000 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizations in the United States. In addition, the likelihood of a severe influenza pandemic caused by a newly emergent strain of the virus is very high, given that three ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Synergistic vaccine adjuvants that stimulate both innate and adaptive immunities
SBC: Bio-Synthesis, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): The objective is to develop a glycoside adjuvant or immune agonist carrying the chemical structures needed to concurrently stimulate in a cooperative manner both innate and adaptive immunities, leading to a synergistic effect on the cellular (Th1) and humoral (Th2) immunities. It is likely that these adjuvants would also stimulate strong mucosal immunity. Studi ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Recombinant antigen diagnostics for filoviruses
SBC: CORGENIX MEDICAL CORPORATION Topic: NIAIDDESCRIPTION (provided by applicant): Viral hemorrhagic fevers (VHFs) are serious, often fatal, illnesses characterized by high fever, damage to the vascular system and multiorgan failure. Our team has successfully produced prototype Lassa virus ELISA that are based on recombinant proteins rather than on reagents that must be produced in high containment laboratories. Under the proposed SBIR, we wi ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lactoferrin for the prevention of antibiotic-associated diarrhea in adult
SBC: VENTRIA BIOSCIENCE Topic: NIADESCRIPTION (provided by applicant): Patients treated with antibiotics frequently develop diarrhea. In developed countries, adults, particularly the elderly, experience a higher death rate due to diarrhea than children. Results from in vitro and preliminary in vivo studies lead us to hypothesize that oral administration of recombinant human lactoferrin as a medical food might be able to prevent an ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A Novel CNS-Penetrable Antiretroviral
SBC: Jericho Sciences, LLC Topic: NIMHDESCRIPTION (provided by applicant): Since the introduction of highly active antiretroviral therapy (HAART) in the mid-1990's for treatment of human immunodeficiency virus type 1 (HIV-1) infection, overall incidence rates of associated neurological maladies have declined. Unfortunately, the HIV-associated prevalence of both central nervous system (CNS) and peripheral nervous system (PNS) disorder ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health